Dr Modi on Updated OS Data From the DESTINY-Breast04 Trial of T-DXd in HER2-Low Breast Cancer
November 15th 2023Shanu Modi, MD, discusses updated survival data from the phase 3 DESTINY-Breast04 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with HER2-low metastatic breast cancer.
Read More
Patient Profile 1: 62-Year-Old Woman With Metastatic Breast Cancer
May 19th 2022Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.
Read More